1-20 of 89
Christoph Heuck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Clinical Trials & Observations
Ola Landgren, Thomas J. Prior, Tara Masterson, Christoph Heuck, Orlando F. Bueno, Ajeeta B. Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A. Ross, Mihaela Talpes, Jay R. Hydren, Jennifer M. Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald Marti, Sean M. Devlin
Journal: Blood
Blood (2024) 144 (4): 359–367.
https://doi.org/10.1182/blood.2024024371
Published: 2024
Includes: Supplemental data
Journal Articles

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Onsay Lau, Cuc Davis, Thomas Renaud, Jaszianne Tolbert, Brandi W Hilder, Tara J Masterson, Michela Campagna, Christoph Heuck, Ajai Chari, Niels WCJ van de Donk, Raluca Verona
Journal: Blood
Blood (2023) 142 (Supplement 1): 1933.
https://doi.org/10.1182/blood-2023-187755
Published: 2023
Journal Articles

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Carolina Schinke, Cyrille Touzeau, Albert Oriol, María-Victoria Mateos, Don A. Stevens, Leo Rasche, Xiang Qin, Kelly Kato, Timothy Ming, Eva G Katz, Katharine S Gries, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Philippe Moreau, Jesús San-Miguel, Paula Rodríguez Otero, Ajai Chari
Journal: Blood
Blood (2023) 142 (Supplement 1): 6711.
https://doi.org/10.1182/blood-2023-189151
Published: 2023
Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Larysa Sanchez, Carolina Schinke, Amrita Krishnan, Jésus G Berdeja, Niels WCJ van de Donk, María Victoria Mateos, Ajai Chari, Samir Parekh, Tarek H. Mouhieddine, Sundar Jagannath, Nizar J Bahlis, Cyrille Touzeau, Albert Oriol, Jesus San-Miguel, Paula Rodriguez Otero, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Kathleen Gray, Damiette Smit, Christoph Heuck, Leo Rasche
Journal: Blood
Blood (2023) 142 (Supplement 1): 2007.
https://doi.org/10.1182/blood-2023-182330
Published: 2023
Journal Articles

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert, Xiang Qin, Xuewen Ma, Diego Vieyra, Angelique Langlois, Christelle Courtoux, William Terry, Lixia Pei, Christoph Heuck, Peter Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4418–4419.
https://doi.org/10.1182/blood-2022-162733
Published: 2022
Journal Articles

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Shaji K Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos
Journal: Blood
Blood (2022) 140 (Supplement 1): 7292–7293.
https://doi.org/10.1182/blood-2022-163260
Published: 2022
Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C. Minnema, Jesus Berdeja, Albert Oriol, Niels WCJ Van De Donk, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Leo Rasche, Amrita Y. Krishnan, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Christoph Heuck, Jesús San-Miguel, Philippe Moreau
Journal: Blood
Blood (2022) 140 (Supplement 1): 384–387.
https://doi.org/10.1182/blood-2022-159707
Published: 2022
Journal Articles

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Clinical Trials & Observations
Michele Cavo, Jesus San-Miguel, Saad Z. Usmani, Katja Weisel, Meletios A. Dimopoulos, Hervé Avet-Loiseau, Bruno Paiva, Nizar J. Bahlis, Torben Plesner, Vania Hungria, Philippe Moreau, Maria-Victoria Mateos, Aurore Perrot, Shinsuke Iida, Thierry Facon, Shaji Kumar, Niels W. C. J. van de Donk, Pieter Sonneveld, Andrew Spencer, Maria Krevvata, Christoph Heuck, Jianping Wang, Jon Ukropec, Rachel Kobos, Steven Sun, Mia Qi, Nikhil Munshi
Journal: Blood
Blood (2022) 139 (6): 835–844.
https://doi.org/10.1182/blood.2021011101
Published: 2022
Includes: Supplemental data
Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Clinical Trials & Observations
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, María-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Journal: Blood
Blood (2022) 139 (4): 492–501.
https://doi.org/10.1182/blood.2020010439
Published: 2022
Includes: Supplemental data
Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Jesus F. San-Miguel, MD PhD, Herve Avet-Loiseau, Bruno Paiva, PhD, Shaji K. Kumar, MD, Meletios A. Dimopoulos, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Cyrille Touzeau, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MDMBBS,MBA, Gordon Cook, MD, Michele Cavo, Hang Quach, MDFRACP,FRCPA,MBBS, Jon Ukropec, PhD, Priya Ramaswami, Huiling Pei, PhD, Steven Sun, Jianping Wang, Maria Krevvata, PhD, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, MD, Rachel Kobos, MD, Ming Qi, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134928
Published: 2020
Journal Articles

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Philippe Moreau, MD, Ajai Chari, Mathias Haenel, MD, Albert Oriol, Paula Rodriguez-Otero, MD PhD, Helen McCarthy, PhD FRCPath, Kenshi Suzuki, MD PhD, Vania T. M. Hungria, MD PhD, Anna Sureda Balari, MD PhD, Lauriane Clement-Filliatre, MD, Cyrille Hulin, MD, Hila Magen, MD, Shinsuke Iida, MD PhD, Vladimir Maisnar, MD, Lionel Karlin, MD, Luděk Pour, MD, Cyrille Touzeau, Shiyi Yang, Michele Kosh, Maria Delioukina, Christoph Heuck, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–30.
https://doi.org/10.1182/blood-2020-134935
Published: 2020
Journal Articles

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Melody Luo, PhD, Dolly A. Parasrampuria, PhD, Saad Z. Usmani, MD, Maria-Victoria Mateos, Hareth Nahi, MD PhD, Christoph Heuck, Ming Qi, MD PhD, Steven Sun, Pamela L. Clemens, PhD, Honghui Zhou, Yu-Nien (Tom) Sun, PhD, Steven Xu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3151.
https://doi.org/10.1182/blood-2019-123405
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Hareth Nahi, MD PhD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, PhD, Ming Qi, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1865.
https://doi.org/10.1182/blood-2019-122765
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Maria-Victoria Mateos, MD PhD, Saad Z. Usmani, MD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Nizar Bahlis, MD, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Xiang Qin, Dolly A. Parasrampuria, PhD, Christoph Heuck, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1906.
https://doi.org/10.1182/blood-2019-122501
Published: 2019
Journal Articles

AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation

Ashwin Sridharan, Carolina D. Schinke, MD, George Georgiev, Mariana Da Silva Ferreira, Kith Pradhan, PhD, Yu Xia, PhD, Maya Panjikaran, MS, Gregory Sims, Chirag Bhagat, Armin Graber, Christoph Heuck, MD, Daisy Alapat, MD, Niels Weinhold, PhD, Sarah K Johnson, PhD, Bart Barlogie, MD PhD, Gareth J. Morgan, MD PhD, Ulrich G. Steidl, MDPhD, Britta Will, PhD, Amit Verma, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2706.
https://doi.org/10.1182/blood.V130.Suppl_1.2706.2706
Published: 2017
Journal Articles

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

Craig C Hofmeister, MDMPH, Ajai Chari, Yael Cohen, Andrew Spencer, MD, Peter M. Voorhees, MD, Jane Estell, Christopher P. Venner, Irwindeep Sandhu, Matthew W Jenner, Cathy Williams, Michele Cavo, MD, Niels WCJ Van De Donk, Meral Beksac, Steven Kuppens, Rajesh Bandekar, Tobias Neff, Christoph Heuck, Ming Qi, Hartmut Goldschmidt, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 510.
https://doi.org/10.1182/blood.V130.Suppl_1.510.510
Published: 2017
Journal Articles

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Niels Weinhold, PhD, Shweta S. Chavan, PhD, Leo Rasche, MD, Owen W Stephens, Purvi Patel, Ruslana Tytarenko, Cody Ashby, PhD, Caleb K. Stein, MS, Michael A Bauer, PhD, Christopher P Wardell, PhD, Shayu Deshpande, PhD, Timea Buzder, Gabor Molnar, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Brian A Walker, PhD, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD, Joshua Epstein, DSc, Bart Barlogie, MD PhD, Christoph Heuck, MD, Faith E Davies, MD, Tobias Meissner, PhD, Gareth J Morgan, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3278.
https://doi.org/10.1182/blood.V128.22.3278.3278
Published: 2016
Journal Articles

High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1

Shweta S. Chavan, PhD, Christoph Heuck, MD, Jie He, PhD, Rusiana Tytarenko, Shayu Deshpande, PhD, Purvi Patel, Mark Bailey, MSc, Caleb K. Stein, MS, Owen W Stephens, Niels Weinhold, PhD, Nathan Petty, MS, Doug Steward, Leo Rasche, MD, Michael A Bauer, PhD, Cody Ashby, PhD, Erich Allen Peterson, PhD BS, MS, Shan Zhong, PhD, Michelle Nahas, PhD, Siraj M Ali, MD PhD, Jo-Anne Vergillo, MD, Jeff Ross, MD, Vincent A. Miller, MD, Phillip J Stephens, PhD, Carolina Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD PhD, Tariq I Mughal, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Brian A Walker, PhD
Journal: Blood
Blood (2016) 128 (22): 4416.
https://doi.org/10.1182/blood.V128.22.4416.4416
Published: 2016
Journal Articles

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

Xenofon Papanikolaou, MD, Caleb K. Stein, MS, Ricky D Edmondson, PhD, Veronica Macleod, Ruslana Tytarenko, Bart Barlogie, MD PhD, Joshua Epstein, DSc, Christoph Heuck, MD
Journal: Blood
Blood (2015) 126 (23): 499.
https://doi.org/10.1182/blood.V126.23.499.499
Published: 2015
Journal Articles

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

Christoph Heuck, MD, Shweta S. Chavan, PhD, Caleb K. Stein, MS, Ruslana Tytarenko, Niels Weinhold, PhD, Siraj Ali, MD PhD, Vincent A. Miller, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Meera Mohan, Jeffery Sawyer, Erich Allen Peterson, PhD BS, MS, Michael Bauer, Timothy C. Ashby, Donald Johann, MD MS, Frits van Rhee, MD PhD, Sarah Waheed, MD, Maurizio Zangari, MD, Faith E Davies, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD
Journal: Blood
Blood (2015) 126 (23): 369.
https://doi.org/10.1182/blood.V126.23.369.369
Published: 2015